Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA.
Bioorg Med Chem Lett. 2012 Dec 1;22(23):7019-23. doi: 10.1016/j.bmcl.2012.10.003. Epub 2012 Oct 11.
A previously described aryl sulfonamide series, originally found through HTS, targets GlmU, a bifunctional essential enzyme involved in bacterial cell wall synthesis. Using structure-guided design, the potency of enzyme inhibition was increased in multiple isozymes from different bacterial species. Unsuitable physical properties (low LogD and high molecular weight) of those compounds prevented them from entering the cytoplasm of bacteria and inhibiting cell growth. Further modifications described herein led to compounds that possessed antibacterial activity, which was shown to occur through inhibition of GlmU. The left-hand side amide and the right-hand side sulfonamides were modified such that enzyme inhibitory activity was maintained (IC(50) <0.1 μM against GlmU isozymes from Gram-negative organisms), and the lipophilicity was increased giving compounds with LogD -1 to 3. Antibacterial activity in an efflux-pump deficient mutant of Haemophilus influenzae resulted for compounds such as 13.
先前描述的芳基磺酰胺系列最初是通过高通量筛选发现的,其靶标是 GlmU,这是一种参与细菌细胞壁合成的双功能必需酶。通过结构导向设计,来自不同细菌物种的多个同工酶的酶抑制活性得到了提高。这些化合物不合适的物理性质(低 LogD 和高分子量)阻止它们进入细菌细胞质并抑制细胞生长。本文进一步的修饰导致了具有抗菌活性的化合物,这表明是通过抑制 GlmU 来实现的。对左手侧酰胺和右手侧磺酰胺进行修饰,以保持酶抑制活性(对来自革兰氏阴性生物体的 GlmU 同工酶的 IC50<0.1 μM),并增加脂溶性,使化合物的 LogD 值为-1 到 3。在流感嗜血杆菌的外排泵缺陷突变体中,化合物如 13 具有抗菌活性。